FOLH1 and prostate cancer: reported a microfluidic device integrating focus‐separation speed reduction design and trap arrays for the high‐throughput capture of CTCs.[211] In immunological methods, a series of molecular markers, such as EpCAM (prostate cancer, kidney cancer, bladder cancer), PSMA (prostate cancer), and CK‐8, −18, and −19 (prostate cancer, bladder cancer), have been identified.